Clinical trial
Pharmacology of Cognition in Schizotypal Personality Disorder
NCT00353379 · Icahn School of Medicine at Mount Sinai, Other · Terminated
Key facts
| NCT number | NCT00353379 |
|---|---|
| Title | Pharmacology of Cognition in Schizotypal Personality Disorder |
| Official title | Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder |
| Lead sponsor | Icahn School of Medicine at Mount Sinai, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizotypal Personality Disorder, Personality Disorders |
| Intervention type | Drug |
| Interventions | Guanfacine, Placebo |
| Enrollment | 29 |
| Start date | Sep 1, 1995 |
| Primary completion | May 1, 1997 |
| Completion | May 1, 1997 |
| First posted | Jul 18, 2006 |
| Last update posted | Feb 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: